Journal of Clinical Toxicology
Open Access
ISSN: 2161-0495
ISSN: 2161-0495
Division of Medical and Surgical Sciences, 41121 Modena MO, Italy
Case Report
Clinical Prognosticators in Patients Treated with CDK 4/6 Inhibitors for Hormone Receptors Positive Advanced Breast Cancer
Author(s): Isca Chrystel*, Omarini Claudia, Cortesi Giulia, Moscetti Luca, Barbolini Monica, Dominici Massimo and Piacentini Federico
Background: CDK4/6 inhibitors are the new standard of care in hormonal receptors positive (HR+) advanced
breast cancer (ABC). Phase III trials demonstrated an improvement in survival outcomes in patients with combined
endocrine approach compared to endocrine therapy (ET) alone. The aim of this retrospective study was to assess
prognostic factors for clinical response to CDK4/6 inhibitors.
Methods: All patients receiving CDK4/6 inhibitors from September 2016 to July 2019 were registered in a database.
Data on tumor and patient’s characteristics as well as concomitant medications were collected. Survival data were
analyzed by Kaplan Meier curves and log rank test. Treatment toxicities were graded according to CTCAE v5. A
drug-drug interactions analysis among CDK 4/6 inhibitors and co-administered medications was performed too.. View More»